chufangao/CTO huggingface dataset:
Clinical trial NCT05019950: Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers
Official title: A Randomized, Placebo-Controlled, Double-Blind, Single-Center Study to Evaluate Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers
Sponsor: NImmune Biopharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-28
Primary completion date: 2022-04-28
Completion date: 2022-04-28
Plan to share individual participant data: NO
Clinical trial NCT02213289: PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
Official title: PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 8.0
Start date: 2015-01-20
Primary completion date: 2020-02-01
Completion date: 2020-08-20
Clinical trial NCT03839823: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
Official title: A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
Acronym: RIGHT Choice
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 222.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-25
Primary completion date: 2022-04-12
Completion date: 2023-05-10
Baseline population: The full analysis set comprised all patients to whom study treatment was assigned by randomization.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03338296: Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
Official title: A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
Sponsor: Eisai Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study was terminated as Eisai agreed to voluntarily withdraw Belviq XR from US market.
Enrollment: 278.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-28
Primary completion date: 2020-04-03
Completion date: 2020-04-03
Baseline population: The safety analysis set was the group of participants who received at least 1 dose of study drug and had at least 1 postdose safety assessment.
Limitations and caveats: This study was terminated as Eisai agreed to voluntarily withdraw Belviq extended release (XR) from the United States market after a request from the Food and Drug Administration based on the Agency's analysis of data from the CAMELIA-TIMI 61 cardiovascular outcomes study (NCT02019264).
Clinical trial NCT04558918: Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Official title: A Randomized, Multicenter, Active-comparator Controlled, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult Patients With PNH and Residual Anemia, Despite Treatment With an Intravenous Anti-C5 Antibody.
Acronym: APPLY-PNH
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 97.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-25
Primary completion date: 2022-09-26
Completion date: 2023-03-06
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT04629196: Induction Optimization With Stelara for Crohn's Disease
Official title: Induction Optimization With Stelara for Crohn's Disease
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Other effective drugs have been introduced to market since the beginning of the study.
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-02-16
Primary completion date: 2024-01-17
Completion date: 2024-01-17
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.
IPD time frame: Data will become available beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research
IPD access criteria: The investigator who proposed to use the data upon reasonable request. Requests should be directed to IBD_Research@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT04434300: Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)
Official title: Comparison of the Pharmacokinetic and the Safety of Daptomycin Administered Subcutaneously Compared to the Intravenous Route : a Cross-over Study
Acronym: DAPTOSC
Sponsor: University Hospital, Caen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-15
Primary completion date: 2021-01-15
Completion date: 2021-11-15
Clinical trial NCT02702492: PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
Official title: A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
Acronym: PANAMA
Sponsor: Karyopharm Therapeutics Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: sponsor decision
Enrollment: 60.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-06-30
Primary completion date: 2021-02-01
Completion date: 2021-06-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02709512: Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Official title: Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
Acronym: ATOMIC
Sponsor: Polaris Group (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 249.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-01
Primary completion date: 2022-08-15
Completion date: 2022-08-15
Limitations and caveats: Enrollment stopped early at the recommendation of the DSMB due to interim analysis positive results and because of slow study enrollment related to an evolving treatment landscape for MPM and the COVID-19 pandemic.
Clinical trial NCT04830943: Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia
Official title: The Effectiveness of Cerebrolycin, a Multi-modal Neurotrophic Factor, for Treatment of Post-covid-19 Persistent Olfactory, Gustatory and Trigeminal Chemosensory Dysfunctions: A Pilot Study
Sponsor: Assiut University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 250.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-01
Primary completion date: 2021-09-30
Completion date: 2022-10-30
Plan to share individual participant data: NO
Clinical trial NCT03710889: Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Official title: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Sponsor: Radius Health, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-20
Primary completion date: 2020-07-15
Completion date: 2020-07-15
Plan to share individual participant data: NO
Clinical trial NCT02882308: Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.
Official title: Phase II(Window) Preoperative Study of Olaparib With Cisplatin or With Durvalumab (MEDI4736) or Alone or no Treatment in Patients With Histologically Proven Squamous Cell Carcinoma of the Head and Neck Who Are Candidates for Surgery.
Acronym: OPHELIA
Sponsor: Hellenic Cooperative Oncology Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-10-20
Primary completion date: 2019-12-31
Completion date: 2020-01-10
Clinical trial NCT03203850: Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
Official title: A Phase II, Multicenter, Open-label, Randomized Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis.
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to enrolment challenge
Enrollment: 45.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-11
Primary completion date: 2023-04-17
Completion date: 2023-04-17
Limitations and caveats: The results should be interpreted with caution due to low number of participants enrolled in both arms.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03861598: Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
Official title: A Feasibility Study: Evaluating Carvedilol With Chemotherapy in Second Line Glioblastoma Multiforme and Response of Peripheral Glioma Circulating Tumor Cells
Sponsor: West Virginia University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Due to Covid
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-19
Primary completion date: 2020-08-21
Completion date: 2021-06-17
Plan to share individual participant data: NO
Clinical trial NCT03166761: Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection
Official title: Randomized Prospective Study of Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Steroid Injection
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: recruitment and staffing
Enrollment: 41.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-14
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Baseline population: the other 18 patients with a negative diagnostic response were not included in the study after the negative screen
Plan to share individual participant data: NO
Clinical trial NCT04642638: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Official title: Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Sponsor: Inovio Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: The study was terminated to prioritize Inovio's COVID-19 efforts to advance a heterologous booster strategy and optimize potential impact on global public health.
Enrollment: 1307.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-11-30
Primary completion date: 2022-09-13
Completion date: 2022-09-13
Baseline population: ITT population included all participants who were randomized.
Plan to share individual participant data: YES
IPD sharing description: Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.
IPD time frame: Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.
IPD access criteria: Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.
Clinical trial NCT04240886: Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
Official title: A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds
Acronym: AEGIS
Sponsor: Basilea Pharmaceutica (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The Sponsor made a strategic decision to terminate the study, in order to prioritize a randomized comparative Phase 3 trial in the same indication. This decision was not based on any safety concerns
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-04
Primary completion date: 2022-03-29
Completion date: 2022-05-09
Baseline population: Safety population included all participants who received at least 1 dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT00948324: Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes
Official title: Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Enrollment: 400.0 (ESTIMATED)
Number of arms: 4.0
Start date: 2008-06-30
Primary completion date: 2019-05-31
Completion date: 2021-12-31
Clinical trial NCT03426137: Relieving Acute Pain (RAP) Study: A Pilot Study
Official title: Relieving Acute Pain (RAP): A Pilot Study
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The focus of the project has shifted to publishing a protocol for future trials because we were unable to recruit. Three participants signed the consent forms but withdrew before the randomization.
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-17
Primary completion date: 2019-03-30
Completion date: 2020-01-21
Baseline population: The three participants who gave written consent to participate in the study and signed the HIPAA form withdrew before randomization or starting any study procedures. Therefore there is no data available to report.
Limitations and caveats: Early termination due to logistical and funding issues, which lead to no analyzable data. A protocol paper has been published should other investigators wish to use the study design (DOI: 10.1136/bmjopen-2019-030623).
Plan to share individual participant data: NO
IPD sharing description: IPD will only be shared among study team members.
Clinical trial NCT04807400: Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
Official title: A Phase IIIb, Multicentre, Randomised Controlled Study to Evaluate the Implementation, Preference and Utility for Administration of Inclisiran Sodium in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD-risk Equivalents and Elevated Low Density Lipoprotein Cholesterol (LDL-C) Using a Primary Care Models in the NHS.
Acronym: SPIRIT
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 892.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-07
Primary completion date: 2023-01-13
Completion date: 2023-01-13
Baseline population: Baseline Participants are based on the Full Analysis Set (FAS) population, as primary and secondary analysis are based on the FAS
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03713632: Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
Official title: A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)
Acronym: SUNRISE
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 545.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-02-25
Primary completion date: 2021-09-23
Completion date: 2022-07-19
Baseline population: Full Analysis Set (FAS)
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02499627: Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
Official title: A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen.
Acronym: FIL-BBV
Sponsor: Fondazione Italiana Linfomi - ETS (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: expected accrual not reached
Enrollment: 43.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-12-23
Primary completion date: 2019-09-13
Completion date: 2020-06-30
Clinical trial NCT04916470: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Official title: Effect of Semaglutide 2.4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes
Acronym: STEP HFpEF DM
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 617.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-15
Primary completion date: 2023-10-11
Completion date: 2023-10-11
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT04683029: A Study of Guselkumab in Participants With Systemic Sclerosis
Official title: A Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Guselkumab in Participants With Systemic Sclerosis
Sponsor: Janssen Pharmaceutical K.K. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-24
Primary completion date: 2023-05-17
Completion date: 2024-07-09
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT05321524: Obeticholic Acid in Pediatric Subjects With Biliary Atresia
Official title: A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study, With an Optional Open-Label Extension to Assess the Safety, Tolerability, and Pharmacokinetics of Obeticholic Acid in Pediatric Subjects With Biliary Atresia
Acronym: CARE
Sponsor: Intercept Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: After extensive efforts to improve recruitment, it is deemed not feasible to enroll the requisite number of subjects to generate data needed to meet the study objectives. EMA Paediatric Committee agreed with the Sponsor to terminate this study.
Enrollment: 7.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-07-01
Primary completion date: 2023-03-09
Completion date: 2023-03-09
Clinical trial NCT05557942: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
Official title: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002 (IMPAHCT-FUL)
Acronym: IMPAHCT-FUL
Sponsor: Aerovate Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Results from the parent study (IMPAHCT) demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.
Enrollment: 186.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-11-02
Primary completion date: 2024-08-08
Completion date: 2024-08-08
Baseline population: The Intent-to-treat (ITT) analysis set included all randomized participants.
Clinical trial NCT03547037: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
Official title: A Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Subjects With Advanced Solid Cancers
Sponsor: Janssen Pharmaceutical K.K. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-31
Primary completion date: 2022-07-04
Completion date: 2022-07-04